Literature DB >> 20119625

Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells.

Deyong Yang1, Xishuang Song, Jianing Zhang, Lin Ye, Shujing Wang, Xiangyu Che, Jianbo Wang, Zhiwei Zhang, Lina Wang, Wei Shi.   

Abstract

Livin, X-linked inhibitor of apoptosis (XIAP), and Survivin are three well-known inhibitors of apoptosis almost exclusively over-expressed in cancer cells and are considered potent targets for cancer treatment. In the present study, we found that Livin, XIAP, and Survivin were simultaneously expressed in bladder cancer cells. We speculated that Livin, XIAP, and Survivin might have synergistic effects on cell growth and apoptosis. Our results confirmed that combined knockdown of all these three genes can synergistically inhibit the proliferation and transformation ability of high-grade bladder cancer T24 cells and promote the cell apoptotic sensitivity to chemotherapy. Furthermore, combined knockdown of Livin, XIAP, and Survivin can markedly increase the abundance of active caspase-3, active caspase-7, active caspase-9, and cytosolic Smac. Our findings imply that combined silencing of Livin, XIAP, and Survivin may be a potent multitargeted gene therapy for bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20119625     DOI: 10.1093/abbs/gmp118

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  10 in total

1.  Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer.

Authors:  Jianwen Wang; Xiaodong Zhang; Ping Wei; Junhui Zhang; Yinong Niu; Ning Kang; Yuxiang Zhang; Weili Zhang; Nianzeng Xing
Journal:  World J Urol       Date:  2014-03-05       Impact factor: 4.226

2.  Prognostic value of survivin in patients with non-Hodgkin's lymphoma: a meta-analysis.

Authors:  Chuan He; Zhigang Liu; Jie Ji; Huanling Zhu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer.

Authors:  Darryl T Martin; Jill M Steinbach; Jingchun Liu; Shogo Shimizu; Hristos Z Kaimakliotis; Marcia A Wheeler; Adam B Hittelman; W Mark Saltzman; Robert M Weiss
Journal:  Mol Cancer Ther       Date:  2013-11-12       Impact factor: 6.261

4.  Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy.

Authors:  Doreen Kunze; Kati Erdmann; Michael Froehner; Manfred P Wirth; Susanne Fuessel
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

Review 5.  Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins.

Authors:  Darren Finlay; Peter Teriete; Mitchell Vamos; Nicholas D P Cosford; Kristiina Vuori
Journal:  F1000Res       Date:  2017-04-27

6.  Dual targeting of survivin and X-linked inhibitor of apoptosis protein suppresses the growth and promotes the apoptosis of gastric cancer HGC-27 cells.

Authors:  Yanfeng Li; Wenbo Gao; Yan Ma; Guanyu Zhu; Fuhui Chen; Hongyan Qu
Journal:  Oncol Lett       Date:  2018-07-05       Impact factor: 2.967

7.  Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.

Authors:  Md Tanvir Hasan; Elizabeth Campbell; Olga Sizova; Veronica Lyle; Giridhar Akkaraju; D Lynn Kirkpatrick; Anton V Naumov
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

8.  Expression of the IAP protein family acts cooperatively to predict prognosis in human bladder cancer patients.

Authors:  Xiaochi Chen; Tiezheng Wang; Deyong Yang; Jianbo Wang; Xiancheng Li; Zhongzhou He; Feng Chen; Xiangyu Che; Xishuang Song
Journal:  Oncol Lett       Date:  2013-01-23       Impact factor: 2.967

9.  Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells.

Authors:  Doreen Kunze; Kai Kraemer; Kati Erdmann; Michael Froehner; Manfred P Wirth; Susanne Fuessel
Journal:  Int J Oncol       Date:  2012-07-06       Impact factor: 5.650

10.  Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment.

Authors:  Andrey S Bavykin; Alexandra A Korotaeva; Stanislav V Poyarkov; Alexandr V Syrtsev; Sergei A Tjulandin; Alexandr V Karpukhin
Journal:  Onco Targets Ther       Date:  2013-09-23       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.